KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Work In Process: 2011-2019

Historic Work In Process for Emergent BioSolutions (EBS) over the last 9 years, with Dec 2019 value amounting to $89.7 million.

  • Emergent BioSolutions' Work In Process was N/A to $114.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $114.2 million, marking a year-over-year change of. This contributed to the annual value of $89.7 million for FY2019, which is 13.08% down from last year.
  • Emergent BioSolutions' Work In Process amounted to $89.7 million in FY2019, which was down 13.08% from $103.2 million recorded in FY2018.
  • Emergent BioSolutions' Work In Process' 5-year high stood at $103.2 million during FY2018, with a 5-year trough of $19.8 million in FY2016.
  • For the 3-year period, Emergent BioSolutions' Work In Process averaged around $89.8 million, with its median value being $89.7 million (2019).
  • Its Work In Process has fluctuated over the past 5 years, first slumped by 39.40% in 2016, then surged by 286.46% in 2017.
  • Over the past 5 years, Emergent BioSolutions' Work In Process (Yearly) stood at $32.7 million in 2015, then slumped by 39.40% to $19.8 million in 2016, then skyrocketed by 286.46% to $76.6 million in 2017, then surged by 34.73% to $103.2 million in 2018, then declined by 13.08% to $89.7 million in 2019.